CION Ameerpet
Childhood Soft-Tissue Sarcoma
Rhabdomyosarcoma treatment — understanding your child's options
Medically reviewed by the CION Paediatric Oncology Team · Last reviewed June 2026
Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma in children. Hearing this diagnosis is frightening. This page explains what RMS is, how it is treated, and what you can ask your child's oncology team at every step.
- Tumour board for every child — no single doctor decides the plan alone
- 45-minute consultations — no rushed decisions, all your questions answered
- Free first consultation — transparent costs, no commitment to start treatment
- We walk this journey with you — from diagnosis through treatment and follow-up
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Understanding RMS
Types of rhabdomyosarcoma — what the diagnosis means
RMS is not one disease. The subtype your child's biopsy reveals has a direct effect on how treatment is planned and how intensively the oncology team will approach the case.
Most common — ~60% of cases
Embryonal RMS
Embryonal rhabdomyosarcoma (ERMS) is the most frequently diagnosed subtype and tends to occur in younger children. It most commonly arises in the head and neck region, the orbit, and the genitourinary tract. Embryonal tumours typically have a more favourable biological profile and respond well to combination treatment. Most children with localised embryonal disease, particularly those in favourable anatomical sites, have encouraging outcomes when treated at a specialist centre following established protocols.
Higher-risk subtype
Alveolar RMS
Alveolar rhabdomyosarcoma (ARMS) is the second most common subtype and is generally considered to carry a higher risk. It is more likely to occur in the extremities (arms and legs) and in the trunk, and it tends to spread to lymph nodes and distant sites more readily than embryonal RMS. The tumour cells in alveolar RMS often carry specific chromosomal changes that the pathologist looks for during molecular testing — findings that significantly influence how treatment intensity is calibrated. Treatment for alveolar RMS is typically more intensive than for embryonal disease.
Rare — adults more than children
Pleomorphic RMS
Pleomorphic rhabdomyosarcoma is the rarest subtype and occurs almost exclusively in adults. It is very unusual in children and adolescents. When it does occur in young people, it is treated by a specialist sarcoma team. Because of its rarity, it is unlikely to be the subtype described in a paediatric diagnosis — but it is included here for completeness so that parents who encounter the term can understand where it fits in the broader category of RMS.
Site-specific
Head and neck RMS (parameningeal)
Some RMS tumours that arise in the head and neck region — specifically those near the meninges (the membranes covering the brain and spinal cord), such as tumours of the nasopharynx, middle ear, or infratemporal fossa — are classified as parameningeal. This site carries a specific risk of spread to the central nervous system, which changes how radiation therapy is planned. Parameningeal RMS requires particularly careful evaluation and is always managed by a team that includes a radiation oncologist experienced with this pattern of disease.
Site-specific
Genitourinary RMS
Rhabdomyosarcoma of the bladder and prostate (in boys) or the vagina and uterus (in girls) falls under the genitourinary category. In younger children, these tumours are almost exclusively of the embryonal subtype. Genitourinary RMS is often detected early because urinary symptoms (blood in the urine, difficulty passing urine) or visible tissue protruding from the vaginal opening prompt medical attention. Surgical planning for these tumours carefully weighs complete tumour removal against preserving bladder and reproductive function wherever possible.
Site-specific
Extremity and trunk RMS
RMS of the arms, legs, and trunk is more likely to be alveolar in subtype and to present at a later stage, partly because a soft-tissue lump in a limb may be attributed to an injury before cancer is considered. These tumours may also spread to regional lymph nodes, so sentinel lymph node sampling or lymph node biopsy is commonly performed as part of surgical staging. Treatment involves chemotherapy, surgery, and often radiation therapy, with the specific plan depending on how completely the tumour can be removed.
Warning signs
Signs your child may have RMS — what parents notice first
No single symptom points clearly to this diagnosis, which is why RMS is sometimes detected late. Knowing what to look for gives you the confidence to seek evaluation early.
A lump that is growing. The most common reason a family comes to see an oncologist for RMS is a lump or swelling that has appeared and continues to grow. The lump is usually firm and painless. It may be in the neck, behind the ear, in a cheek, along a limb, in the lower abdomen or pelvis, or anywhere else on the body. Pain is not a reliable early warning sign — most RMS lumps do not hurt, especially at the beginning.
Eye changes. When RMS arises in or around the orbit, parents often notice the eye appearing to bulge forward (proptosis), a drooping upper eyelid, or swelling around the eye that does not look like a typical stye or infection. These changes can develop over days to weeks. Any progressive eye protrusion in a child should be evaluated by a doctor without delay.
Nasal and throat symptoms that do not resolve. Persistent, one-sided nasal congestion that does not respond to usual treatment, unexplained nosebleeds, or a visible mass growing from the inside of the nose can be signs of RMS in the nasal passages. A change in the voice or difficulty swallowing that develops without an obvious infection may indicate a throat or neck mass.
Urinary or pelvic symptoms. Blood in the urine (which may make the urine look pink, red, or brown), difficulty passing urine, or a feeling of fullness in the lower abdomen can occur when RMS involves the bladder, prostate, or pelvic structures. In young girls, tissue that protrudes from the vaginal opening is sometimes the first visible sign of vaginal RMS.
When to act. If your child has a lump that is growing, any of the eye changes described above, or urinary symptoms that have no clear cause, do not wait for a routine check. Ask your paediatrician for an urgent referral to a specialist. Most lumps in children are benign — but the ones that are not cancer are best confirmed quickly, and the ones that are cancer benefit most from early evaluation.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Your child deserves a plan built by a team, not a single opinion
Every child with rhabdomyosarcoma at CION has their case reviewed at a multidisciplinary tumour board before any treatment begins. Decisions for healing, not billing.
The care pathway
How rhabdomyosarcoma chemo, surgery and radiation work together
RMS treatment follows a carefully sequenced programme. Understanding each step helps you ask better questions and feel more in control during a difficult time.
Biopsy and pathology review
Before any treatment can begin, a sample of tissue from the tumour must be taken and examined by a pathologist. This is the biopsy. The pathologist uses specific staining techniques and molecular tests to confirm that the tissue is rhabdomyosarcoma, identify the subtype (embryonal, alveolar, or pleomorphic), and look for specific chromosomal changes in the tumour cells. These molecular findings are not just diagnostic — they are a core part of risk stratification. At CION, the biopsy report is reviewed by an experienced pathologist who specialises in soft-tissue tumours, and the findings are discussed at a multidisciplinary tumour board before a treatment plan is proposed to the family. No treatment begins before this review is complete.
Staging scans and bone marrow assessment
Once the biopsy confirms RMS, a series of scans maps the full extent of the disease. MRI of the primary tumour site gives the most detailed picture of the tumour and its relationship to surrounding structures. CT of the chest is performed to check for spread to the lungs. A bone scan or PET-CT may be used to check whether the cancer has spread to the skeleton. A bone marrow biopsy, taken from the back of the pelvis, checks whether cancer cells are present in the marrow. Together, these investigations produce the staging and surgical group classification that determines the child's risk category and the intensity of treatment they will receive. This staging workup is not a delay — it is the foundation of an accurate treatment plan.
Chemotherapy — the backbone of RMS treatment
Chemotherapy is given to virtually all children with rhabdomyosarcoma, regardless of stage or subtype. It serves two essential roles: systemic treatment (targeting any cancer cells that have spread beyond the visible tumour and cannot be seen on scans) and tumour shrinkage (reducing the size of the primary tumour before surgery, which may make complete removal possible while preserving more normal tissue and function). The duration and intensity of chemotherapy depends on the risk category. Children in the low-risk group receive a shorter, less intensive course. Those in the intermediate- or high-risk group receive a longer, more intensive programme. Chemotherapy for RMS typically follows a published protocol from the Children's Oncology Group (COG), which represents decades of carefully conducted clinical trials. Your child's oncologist will explain which protocol is being used and what to expect during treatment.
Surgery — removing the tumour while preserving function
Surgery is a central part of RMS treatment for most children. The aim is to remove the tumour with clear margins — meaning no cancer cells are left at the edges of what is removed. However, complete removal is not always possible at first presentation, particularly when the tumour is in a site such as the orbit, bladder, or nasopharynx where removing all surrounding tissue would cause significant disability. In these situations, chemotherapy is given first to shrink the tumour, and surgery is performed after the tumour has reduced in size. This approach often allows a smaller, more precise operation while still achieving adequate tumour clearance. For tumours in the extremities or trunk, surgery may also include sampling of the lymph nodes in the region to check for microscopic spread. Every surgical plan is designed in advance by the multidisciplinary team, not decided in the operating room alone.
Radiation therapy — targeting residual disease
Radiation therapy is added to the treatment plan for most children with RMS whose tumour was not completely removed by surgery (Groups II–IV), or whose tumour site makes complete surgery impossible without causing major harm. Radiation is directed precisely at the tumour site and, where relevant, at regional lymph node areas. The timing of radiation relative to chemotherapy and surgery is carefully planned. For parameningeal tumours — those near the membranes covering the brain and spinal cord — the radiation field and technique require particular expertise to balance effective treatment against protecting adjacent brain structures. At CION, radiation therapy is planned and delivered by radiation oncologists with specific experience in paediatric cases, using modern techniques that minimise dose to healthy tissue while treating the tumour effectively.
Supportive care throughout treatment
Treatment for rhabdomyosarcoma is intensive, and the child's wellbeing during treatment matters as much as the treatment itself. Supportive care at CION includes nutritional support — because maintaining adequate nutrition during chemotherapy significantly affects how well children tolerate treatment; management of nausea, infection risk, and pain; emotional and psychological support for both the child and the family; and coordination with the school and community so that the child's life outside the hospital remains as normal as possible. Decisions about supportive care are made alongside the oncology plan, not as an afterthought. You deserve a care team that sees the whole child, not just the tumour.
Follow-up and long-term survivorship
After active treatment ends, the oncology team schedules regular imaging and clinical reviews at defined intervals. The frequency of these reviews is highest in the first two years after treatment, when the risk of recurrence is greatest, and then reduces gradually over time. Long-term follow-up also monitors for late effects of treatment — effects that can appear months or years after therapy is complete. These may include effects on growth, hearing, heart or lung function, or fertility, depending on what treatment was given and which part of the body was in the treatment field. The care team at CION plans this follow-up programme from the start of treatment, not after it ends. We walk this journey with your family all the way through — from diagnosis to the day you no longer need us.
We walk this journey with you
Hear from families who have been where you are
Every family's journey is different. What is the same is our commitment: a tumour board for every child, a 45-minute consultation with no rushed decisions, and transparent costs from day one.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Your questions about rhabdomyosarcoma — answered
What is rhabdomyosarcoma (RMS) and why does it affect children?
Rhabdomyosarcoma, often shortened to RMS, is a cancer that begins in cells called rhabdomyoblasts — the precursor cells that are meant to develop into skeletal muscle. Skeletal muscle is the kind of muscle we consciously control, such as the muscles in the arms, legs, and face. Despite its name, RMS does not always arise in or near a muscle; it can grow in sites where skeletal muscle is not normally found, including the orbit (eye socket), nasal passages, throat, bladder, and bile ducts. This is because rhabdomyoblasts are scattered throughout the developing body in early foetal life. RMS is primarily a disease of children and adolescents. The great majority of cases are diagnosed before the age of 18, with two peaks of incidence: one in early childhood (ages 2–6) and a second, smaller peak in early adolescence. It is the most common soft-tissue sarcoma in children. The exact cause is not known in most cases. No environmental exposure, dietary factor, or anything a parent did during pregnancy is recognised as a cause. A very small proportion of cases occur in children with certain rare inherited conditions, but the large majority arise sporadically.
What are the warning signs of rhabdomyosarcoma a parent should know?
The warning signs of rhabdomyosarcoma depend strongly on where in the body the tumour is growing, which makes early recognition challenging because no single symptom points clearly to this diagnosis. Common presentations include: a painless but growing lump or swelling anywhere on the body, particularly in the head and neck region, the extremities, or the pelvis; a lump behind or around a child’s eye that causes the eye to bulge forward (proptosis) or drooping of the eyelid; persistent nasal congestion, nosebleeds, or a mass growing from the nasal cavity; difficulty swallowing or a change in the voice if the tumour is in the throat; blood in the urine or difficulty passing urine if the tumour involves the bladder; or a lump or asymmetry in the trunk, pelvis, or limbs. The critical point is that any lump that is growing, that does not have an obvious explanation, or that is associated with other symptoms deserves prompt medical evaluation. A lump in a child is not necessarily cancer, but it must be properly assessed — early evaluation leads to earlier diagnosis.
How is rhabdomyosarcoma diagnosed?
Diagnosis begins with a detailed clinical examination and imaging studies. An ultrasound may be the first scan used if the lump is accessible; CT scans and MRI scans give a more detailed picture of the tumour and help define its boundaries. Imaging of the chest, abdomen, and bones is carried out to check whether the cancer has spread to the lungs, lymph nodes, or skeleton. A bone marrow biopsy is performed because RMS can occasionally involve the bone marrow. The definitive step is a biopsy — taking a piece of tissue from the tumour and examining it under the microscope. The pathologist uses specific stains and molecular tests on the biopsy tissue to confirm the RMS diagnosis and identify the subtype (embryonal, alveolar, or pleomorphic), because the subtype has a significant influence on how treatment is planned. At a specialist paediatric oncology centre, the biopsy report is reviewed by an experienced pathologist as part of a multidisciplinary team discussion before any treatment begins.
What are the stages and risk groups in rhabdomyosarcoma?
Rhabdomyosarcoma is classified using two parallel systems that together determine treatment intensity. The first is a clinical staging system (Stages 1–4) based on the site of the tumour, its size, and whether the cancer has spread to lymph nodes or distant organs. Stage 1 includes tumours in certain ‘favourable’ sites such as the orbit, head and neck areas away from the meninges, and the urogenital tract. Stage 4 means there is spread to distant sites such as the lungs, bones, or bone marrow. The second is a surgical grouping (Groups I–IV) based on how completely the surgeon was able to remove the tumour. Group I means the tumour was completely removed; Group IV means distant spread is present. Together, staging and surgical group are used to place each child into a low-risk, intermediate-risk, or high-risk treatment category. The subtype (embryonal vs alveolar) adds another critical layer — alveolar RMS is generally considered higher risk and receives more intensive treatment. Understanding where your child’s disease falls in this system is one of the first conversations you will have with the paediatric oncology team.
How is rhabdomyosarcoma treated?
Treatment for rhabdomyosarcoma uses a combination of chemotherapy, surgery, and radiation therapy, delivered in a carefully planned sequence that is tailored to the child’s risk group and disease site. Chemotherapy is the backbone of RMS treatment and is given to all children with this diagnosis — both to treat any cancer that cannot be seen on imaging and to shrink the primary tumour before surgery. Surgery aims to remove the tumour while preserving as much normal function as possible; in sites such as the orbit or bladder, the surgical approach is carefully planned to avoid permanent disability. Radiation therapy is added in most cases where surgery has not completely removed the tumour, or where the tumour site means complete removal is not possible without causing significant harm. For low-risk disease, treatment is less intensive and outcomes are generally very encouraging. For intermediate- and high-risk disease, treatment is more intensive and longer. Every child’s treatment plan at CION is built by a multidisciplinary tumour board that includes medical oncologists, surgical oncologists, radiation oncologists, and supportive care specialists. We walk this journey with your family — from diagnosis through to the end of treatment and the follow-up period beyond.
What should a family expect after rhabdomyosarcoma treatment ends?
After active treatment ends, regular follow-up is essential. The oncology team will schedule imaging and clinical assessments at defined intervals to check for any recurrence and to monitor the effects of treatment on the growing child. Potential late effects — effects of treatment that appear months or years after therapy is complete — depend on the type of treatment received, the site treated, and the child’s age at treatment. These can include changes in growth, effects on fertility, heart or lung function if those areas were in the radiation field, or changes related to surgery. A specialist team will monitor these proactively and refer to appropriate subspecialists as needed. The transition back to school and everyday life is also something the care team at CION supports actively. You deserve full information about what to watch for, what follow-up looks like, and how to ask for help if new symptoms appear. Long-term survivorship care is a planned, coordinated part of what we offer — not an afterthought.
Pediatric Cancer A–Z
Explore All Pediatric Cancer Topics
Browse our complete library of parent-facing guides, grouped by topic — from warning signs and cancer types to diagnosis, treatment, side-effect care, survivorship and family support.